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Rationale: Despite its widespread use in oncology, the PET radiotracer 18F-FDG is ineffective for 
improving early detection of pancreatic ductal adenocarcinoma (PDAC). An alternative strategy 
for early detection of pancreatic cancer involves visualisation of high-grade pancreatic 
intraepithelial neoplasias (PanIN-3), generally regarded as the non-invasive precursors of PDAC. 
The DNA damage response is known to be hyper-activated in late-stage PanINs. Therefore, we 
investigated whether the SPECT imaging agent, 111In-anti-γH2AX-TAT, allows visualisation of 
the DNA damage repair marker γH2AX in PanIN-3s in an engineered mouse model of PDAC, to 
facilitate early detection of PDAC.  
Methods: Genetically engineered KPC mice (KRasLSL.G12D/+; p53LSL.R172H/+; PdxCre) were imaged 
with 18F-FDG and 111In-anti-γH2AX-TAT. PanIN/PDAC presence visualised by histology was 
compared with autoradiography and immunofluorescence. Separately, the survival of KPC mice 
imaged with 111In-anti-γH2AX-TAT was evaluated. 
Results: In KPC mouse pancreata, γH2AX expression was increased in high-grade PanINs, but 
not in PDAC, corroborating earlier results obtained from human pancreas sections. Uptake of 111In-
anti-γH2AX-TAT, but not 111In-IgG-TAT or 18F-FDG, within the pancreas was positively 
correlated with the age of KPC mice, which was correlated with the number of high-grade PanINs. 
111In-anti-γH2AX-TAT localises preferentially in high-grade PanIN lesions, but not in established 
PDAC. Younger, non-tumour-bearing KPC mice that show uptake of 111In-anti-γH2AX-TAT in 
the pancreas survive significantly shorter than mice with physiological 111In-anti-γH2AX-TAT 
uptake. 
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Conclusion: 111In-anti-γH2AX-TAT imaging allows non-invasive detection of DNA damage 
repair signalling upregulation in pre-invasive PanIN lesions and is a promising new tool to aid in 
the early detection and staging of pancreatic cancer.  




Globally, the number of pancreatic cancer cases is predicted to reach 484,486 by 2020 (1). 
Approximately 90% of these patients will have pancreatic ductal adenocarcinoma (PDAC) which 
has a dismal 5-year survival rate of <5% (2). PDAC is projected to become the second-most 
frequent cause of cancer-related death by 2030. As current PDAC therapies are only minimally 
effective, the best chance of a cure is surgical resection. Most patients, however, are ineligible for 
surgery as they are diagnosed at an advanced stage, when the cancer has already spread beyond 
the pancreas. Encouragingly, if PDAC is detected when it is still confined to the pancreas, in 
approximately 15% of cases, the 5-year survival rate following surgery markedly increases to 25% 
(3), and may be improved even further by neoadjuvant chemotherapy (4). Therefore, the most 
effective strategy for improving PDAC survival is to detect its presence earlier so that more 
patients can benefit from life-extending and potentially curative surgery. 
Pancreatic cancer diagnosis usually depends on anatomical imaging techniques such as 
computed tomography, endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, 
laparoscopy, and magnetic resonance imaging (5). This information is then used in conjunction 
with analysis of serum biomarkers (such as CA19-9 (6)) and biopsied tissue to confirm the 
diagnosis and stage of the disease (5). A major limitation of the aforementioned imaging 
techniques is that none are sufficiently sensitive to reliably detect the molecular biomarkers of 
PDAC formation which arise before the manifestation of anatomical abnormalities (7). In contrast, 
nuclear imaging techniques such as positron emission tomography (PET) and single photon 
computed tomography (SPECT) do offer the required sensitivity (7). Unfortunately, however, the 
most widely utilised PET imaging agent, 18F-fludeoxyglucose (18F-FDG), has been found to be 
ineffective for improving early detection of PDAC (7,8). The failure of this agent ‒ which reveals 
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abnormal glucose metabolism ‒ is largely due to its inability to distinguish PDAC from chronic 
inflammation associated with focal mass-forming pancreatitis (8). 
An emerging alternative strategy for early detection of PDAC involves detection of high-
grade pancreatic intraepithelial neoplasias (PanIN-3) (9). Indeed, it has been suggested that the 
greatest hope for saving lives that otherwise would be lost to pancreatic cancer might be the early 
detection of PanIN precursor lesions (10). PanINs are the most common precursor of PDAC and 
range from PanIN-1-3 according to the degree of dysplasia (10).  
High-grade PanIN-3 lesions have most diagnostic value as, unlike the lower grade lesions, 
these are more likely to culminate in invasive carcinoma, and are generally regarded as a canonical 
precursor to PDAC. Unlike PanIN-1 or -2, PanIN-3 lesions are present at very low frequencies in 
individuals with an otherwise healthy pancreas (4%), and then only in older patients, but more so 
in individuals with a familial background of PDAC (11), or with pancreatitis – known risk factors 
for PDAC (12), whereas PanIN-3s are present in 70% of PDAC patients. Given the difficulty to 
assess PanIN-3 burden non-invasively, no direct correlation with progression to PDAC can be 
made. However, a recent report using lineage analysis by Makohon-Moore et al. showed strong 
genetic relationships among high-grade PanINs, and PDAC lesions from the same patient (13), 
confirming the model of step-wise progression from PanIN-3 to PDAC (14). Taken together, this 
suggests that detection of PanIN-3 lesions may assist in early detection of PDAC tumorigenesis. 
One attractive molecular biomarker of high-grade PanIN-3 lesions is the DNA damage 
response (DDR) protein γH2AX which arises through phosphorylation of the histone H2A variant 
H2AX, and is upregulated following cellular activation of DDR signalling . The DDR machinery, 
including γH2AX, is well-known to be elevated during the development of several cancer types 
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(15,16), including pancreatic cancer (17). Koorstra et al. showed that γH2AX has a favourable 
timeline of expression as an early detection biomarker as it is highly upregulated during the 
development of the pre-invasive PanIN-3 lesions and expressed far less in normal tissue and overt 
PDAC (18). Similar results were previously obtained by Bartkova et al., showing DDR activation 
in bladder, breast, and colon cancer precursor lesions (15). 
We previously developed a SPECT imaging agent, 111In-anti-γH2AX-TAT (19-22), and an 
alternative PET imaging agent, 89Zr-anti-γH2AX-TAT (23), which permitted non-invasive 
visualisation and quantification of upregulated γH2AX during tumorigenesis in a mouse model of 
breast cancer (20), and monitoring of response to cancer therapy in mice bearing murine PDAC 
allograft tumours (19). Here, employment of the 111In-labelled SPECT imaging agent allowed 
concommittant comparison by PET imaging with 18F-FDG. In the present study, we demonstrate 
the potential of this DNA damage imaging agent for the detection of high-grade PanINs during 
PDAC development in the genetically engineered KPC (KRasLSL.G12D/+; p53LSL.R172H/+; PdxCre) 
mouse model, as a proxy for the human disease.  
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MATERIALS AND METHODS  
Immunoconjugate preparation and radiosynthesis of 111In-anti-γH2AX-TAT and 111In-
IgG-TAT was performed using previously described methods (19), from mouse monoclonal anti-
γH2AX antibody (Merck, clone JBW-301), or isotype-matched IgG control antibody. 
All animal procedures were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and with local ethical committee approval. Genetically engineered KPC 
mice (K-rasLSL.G12D/+; p53R172H/+; PdxCre) and BALB/c mice were housed in IVC cages in sex-
matched groups of up to 5 per cage in an artificial day-night cycle facility with ad libitum access 
to food and water. 
γH2AX imaging was performed 24 h after intravenous administration of 111In-anti-
γH2AX-TAT (5 MBq, 5 µg). 111In-IgG-TAT (5 MBq, 5 µg) was used as a control. In some cases, 
mice were also concurrently imaged using 18F-FDG (approximately 7.5 MBq), 1 h after 
intravenous administration. Mice were fasted 4 hours prior to 18F-FDG injection. Groups of KPC 
mice were randomised for gender, whereas wild type mice (BALB/c) that were used as controls 
were all female. PET/SPECT/CT images were acquired using a VECTor4CT scanner (MILabs, 
Utrecht, the Netherlands). For full experimental details, reconstruction and acquisition parameters, 
see Supporting Information. 
At various ages (ranging from 70 to 224 days), KPC mice underwent concomitant imaging 
with 18F-FDG, and 111In-anti-γH2AX-TAT (n = 9) or 111In-anti-IgG-TAT (n = 8). After imaging, 
pancreas tissue was harvested and processed as below. 
To investigate the effect of pancreatic inflammation on 111In-anti-γH2AX-TAT uptake, in 
a separate study, BALB/c mice (n = 4 per group) were administered caerulein via a series of six 
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hourly intraperitoneal injections to induce acute pancreatitis (24). 111In-anti-γH2AX-TAT was 
administered intravenously 150 min after the last caerulein injection, and SPECT/CT imaging was 
performed 24 h later.  
In addition, we performed a study comparing the biodistribution of 111In-anti-γH2AX-TAT 
in younger BALB/c wild type (wt) mice (aged 66-76 days, n = 3) and older mice (aged 500-506 
days, n = 3).  
Separately, younger KPC mice (aged 66-77 days) without tumours (the lack of a tumour 
was confirmed on necropsy) were imaged by SPECT, 24 h after administration of 111In-anti-
γH2AX-TAT (n = 10) or 111In-IgG-TAT (n = 8) as above. Survival of mice was followed for up 
to 64 days after SPECT imaging. 
To evaluate the influence of an existing tumour on the uptake of 111In-anti-γH2AX-TAT in 
KPC mice, imaging was performed 24 h after intravenous administration of 111In-anti-γH2AX-
TAT (n = 9) or 111In-IgG-TAT (n = 7). Tumour presence was confirmed on necropsy (10 mice 
with tumour and 6 mice without). 
To determine the influence of age on the distribution of 111In-anti-γH2AX-TAT, three 
younger (aged 66-76 days) and three older Balb/c mice (aged 500-506 days) were intravenously 
injected with 111In-anti-γH2AX-TAT. 
Mice were euthanised by cervical dislocation and selected organs, tissues and blood were 
removed, and the percentage of the injected dose per gram (%ID/g) of each sample was calculated. 
Pancreatic tissue was flash-frozen with dry ice and stored at -80°C until required for further 
processing. 
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Autoradiography and Histological Analysis 
Sections of pancreas tissue were exposed to a storage phosphor screen (PerkinElmer) to 
generate autoradiographs. The same ex vivo tissue sections were characterised by 
immunofluorescence, haematoxylin and eosin (H&E) and/or DAB (3,3′-Diaminobenzidine) 
staining to probe γH2AX expression and to determinine PanIN/PDAC status (as defined by Hruban 
et al. (10)). Morphological analysis was checked and endorsed by a qualified pathologist (RG). 
Full experimental details are provided in the Supplemental Information. 
Statistical Analyses 
All statistical and regression analyses were performed using GraphPad Prism v7 (GraphPad 
Software, San Diego, CA, USA). Linear regression with Runs test was used to check for 
correlations between measurements. After testing for normality using a Shapiro-Wilk test, means 
were compared using a t-test with Welch’s correction for non-equal variances. One-way ANOVA 
tests followed by Dunnet’s post-tests were used to compare multiple groups. Two-way ANOVA 
tests were used to analyse grouped data. All results are reported as mean ± standard deviation of 
at least three independent replicates, unless otherwise indicated.  




γH2AX Is Upregulated during PDAC Development in KPC Mice 
Using a set of pancreatic tissues obtained from KPC mice at different ages, we set out to 
investigate γH2AX expression during PDAC development. KPC mice exhibit invasive PDAC 
from 2 months of age onwards, with co-presentation of precursor lesions (25). Following 
histological classification of tissues, we confirmed the general relationship between PanIN 
presentation and age in our KPC mouse colony, with older animals presenting increasing amounts 
of all PanIN precursor lesions (P < 0.0001), including high-grade PanINs (P = 0.0203) 
(Supplemental Fig. 1A). Tumour formation in our colony occurred over a large interval with 
animals first showing FDG-avid lesions between 70 and 220 days of age. We observed no liver 
metastases in KPC mice in our colony. 
We showed that this genetically engineered mouse model reproduces the hyperactivation 
of the DDR machinery observed in human PanINs and PDAC, as measured by γH2AX 
immunostaining (Fig. 1), first reported by Koorsta et al. (18), which themselves corroborated 
results from Bartkova et al. who showed DNA damage signalling hyperactivation in a large range 
of precursor lesions in other cancer sites (15). We observed little or no γH2AX staining in normal 
acinar tissue, in the earlier precursor lesions (PanIN-1), or in areas of marked lymphocyte 
infiltration; and little in PanIN-2 lesions and in regions of PDAC. However, there was marked 
γH2AX staining in all areas of high-grade precursor lesions (PanIN-3s). Previous reports showed 
very few cells expressing γH2AX foci in pancreata harvested from KC mice that only develop 
PanIN-1 and -2 lesions, since they lack the p53 mutation of KPC mice (26). 
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Since DNA laddering in the late stages of apoptosis also leads to pan-nuclear γH2AX 
expression, we evaluated apoptosis in sections of pancreata from KPC mice by staining for 
activated caspase-3 (Supplemental Fig. 2). Only in lymphocyte infiltrates, but not in PDAC or 
PanIN lesions was significant activated caspase-3 observed, suggesting that the γH2AX signal 
observed in PanIN-3 lesions is not a result of apoptosis. 
In vivo Imaging of γH2AX in KPC Mice 
In an effort to visualise this DDR activation in KPC mice in a non-invasive manner, we 
performed SPECT/CT imaging 24 h after intravenous administration of 111In-anti-γH2AX-TAT 
(or the non-specific control, 111In-IgG-TAT) to KPC mice of various ages. Mice that were 
administered 111In-IgG-TAT yielded SPECT images that were consistent with the typical 
biodistribution of a radiolabelled antibody (Fig. 2, Supplemental Fig. 3). 
In contrast, some younger and all older KPC mice that were administered 111In-anti-
γH2AX-TAT showed marked upper abdominal uptake, as well as the physiological signal 
observed in blood, heart, and liver as observed for 111In-IgG-TAT (Fig. 2). Upper abdominal 
uptake of 111In-anti-γH2AX-TAT was higher in older KPC mice. After removal of tissues from the 
mice, we quantified tracer uptake in a selected range of tissues (summarised in Supplemental Fig. 
4). No age-related effects were seen after 111In-IgG-TAT administration in any of the organs, 
including the pancreas (R = 0.41, P>0.05), indicating there were no non-target-specific or 
clearance-related effects. In contrast, after 111In-anti-γH2AX-TAT administration a significant 
correlation of pancreatic uptake with age was revealed (R = 0.83, P = 0.0015) (4.7±0.92 vs. 
6.6±0.56%ID/g in younger vs. older animals; P = 0.0098), but not in any of the other organs. This 
correlated with increased prevalence of PanIN3 lesions, reduced percentage of healthy pancreas, 
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and total increase in the relative area of PanIN lesions (Supplementaal Figs. 1B-D), and an 
increased uptake of 111In-anti-γH2AX-TAT in the pancreas of tumour-bearing animals compared 
to non-tumour-bearing animals (where the presence or absence of a tumour was confirmed on 
necropsy; P = 0.015; Supplemental Fig. 5A). The biodistribution of 111In-anti-γH2AX-TAT was 
not significantly different from that in age-matched wild-type BALB/c animals (aged 66-76 days; 
Supplemental Fig. 5B). In addition, we found no difference between organ uptake between 
younger and older BALB/c wild type animals (aged 50-506 days; P>0.05; Supplementa. Fig. 5), 
suggesting that the increase in 111In-anti-γH2AX-TAT uptake in the pancreas was not merely 
related to ageing of the animals. 
Given the different energies of the gamma-rays emitted by 111In (171 and 245 keV) or 18F 
(511 keV following annihilation of the positron emitted by the decaying radionuclide), we were 
able to image and quantify 111In-anti-γH2AX-TAT and 18F-FDG simultaneously (Fig. 2). In 
contrast to 111In-anti-γH2AX-TAT imaging, we found no significant correlation between 18F-FDG 
uptake in any of the organs with age, or PanIN stage (Supplemental Fig. 4C), corroborating earlier 
reports in human subjects where 18F-FDG-PET imaging was of little utility for early detection of 
PDAC (7,8). Similarly, no difference was observed between total pancreatic uptake of 18F-FDG in 
BALB/c animals versus KPC mice (P = 0.86; Supplemental Fig. 5B). 
γH2AX Imaging in KPC Mice Correlates with Age and PanIN Stage 
Assessment of 111In-anti-γH2AX-TAT uptake in total pancreas of KPC mice, as measured 
by ex vivo gamma counting, revealed a clear correlation between the weight-normalized uptake of 
the tracer and the age of the mice (R = 0.83, P = 0.0015; Fig. 3), which in turn correlated with 
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PanIN extent (P < 0.0001; Supplemental Fig. 1A). This was not the case for the non-specific 
control compound 111In-IgG-TAT (R = 0.41, P = 0.32). 
Comparing the uptake of 111In-anti-γH2AX-TAT in the pancreas with histological analysis, 
we found a trend towards correlation with the reduction in histologically normal pancreas tissue 
and increased uptake (R = 0.69, P = 0.08; Supplemental Fig. 1C). This trend was not observed for 
111In-IgG-TAT (R = 0.058, P = 0.9). In agreement with this, a clear correlation was also observed 
for the coverage of total PanIN lesions and pancreatic uptake of 111In-anti-γH2AX-TAT (R = 0.73, 
P = 0.031), but not with 111In-IgG-TAT (R = 0.0015, P = 0.99) (Supplemental Fig. 1D). 
111In-anti-γH2AX-TAT Is only Taken up in High-grade PanIN Lesions 
To confirm that systemically delivered 111In-anti-γH2AX-TAT co-localizes with high-
grade PanIN lesions in vivo, we performed autoradiography and immunohistochemistry probing 
for γH2AX on sections of pancreatic tissue obtained from KPC mice (Fig. 4, additional sections 
shown as Supplemental Fig. 6). In line with our earlier results that γH2AX expression was mostly 
observed in high-grade PanIN-3 tissue, a significantly higher autoradiography signal was observed 
in high-grade PanIN-3s after administration of 111In-anti-γH2AX-TAT, compared to normal 
pancreas, early PanIN lesions, lymphocyte infiltrates or PDAC, although some background uptake 
was observed in normal pancreas tissue. Quantitative analysis of autoradiographs following 111In-
anti-γH2AX-TAT imaging corroborated this observation, with high-grade PanIN lesions showing 
an uptake of the radiolabelled compound of 9.01 ± 0.72%ID/g versus 6.35 ± 0.51%ID/g for the 
total pancreas (P<0.0001), lymphocyte infiltrates (P = 0.0001), PanIN2 lesions (P = 0.003) or 
PDAC tissue (P = 0.0073) (Fig. 4F). No such correlation was observed in mice that were 
administered 111In-IgG-TAT (P>0.05; Fig. 4G). Although we onserved a small increase in γH2AX 
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staining in PanIN2 lesions upon immunohistochemical analysis, this did not result in a significant 
increase of the uptake of 111In-anti-γH2AX-TAT in these lesions, as measured by autoradiography 
(P > 0.05). 
In addition, we observed no increased uptake of 111In-anti-γH2AX-TAT in lymphocyte 
infiltrates, compared to normal pancreas (P = 0.0001). Furthermore, in a separate study, no 
increased uptake of 111In-anti-γH2AX-TAT was measured in the pancreas of mice with caerulein-
induced acute pancreatitis (P>0.05; Supplemental Fig. 7). 
111In-anti-γH2AX-TAT Uptake Predicts Onset of PDAC in KPC Mice 
After showing that 111In-anti-γH2AX-TAT is taken up preferentially in high-grade PanINs 
(i.e. PanIN-3s), and given that these lesions are regarded as direct precursors of PDAC, we 
evaluated, in a separate study, the ability of SPECT imaging with 111In-anti-γH2AX-TAT to 
predict tumour formation and survival. KPC mice aged between 66-77 days were imaged by 
SPECT, 24 h after administration of 111In-anti-γH2AX-TAT (n = 11) or control imaging agent 
111In-IgG-TAT (n = 8). Mice with increased uptake of 111In-anti-γH2AX-TAT in the pancreas 
region (as indicated in Fig. 5A) survived significantly shorter than those with little discernible 
uptake (median survival 22 days vs. more than 63 days, respectively; P = 0.0273). No such 
observation was made in mice imaged with 111In-IgG-TAT (all scans showed little to no uptake in 
the pancreas region, similar to Fig. 2C). All images obtained are shown in Supplemental Fig. 7. 
Mice were randomly assigned to 111In-anti-γH2AX-TAT or 111In-IgG-TAT imaging cohorts, 
which had no influence on survival (P>0.05; Supplemental Fig. 8). In addition, no correlation was 
found between the age at which these animals were imaged and their survival after the scan 
(P>0.05; Supplemental Fig. 8). Together with the observation that no increased uptake of 111In-
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anti-γH2AX-TAT is detected in age-matched wild-type mice (Supplemental Fig. 5B), our results 
suggest that visualising the high-grade PanIN-3 lesions using 111In-anti-γH2AX-TAT can be used 
as an indicator of PDAC development in KPC mice. A caveat here is that of course all KPC mice 
will eventually grow tumours. The true specificity and selectivity of the method can therefore not 
be determined using the experimental setup in this proof-of-principle study. 
In a separate study, we evaluated the effect of the presence or not of a tumour (confirmed 
on necropsy), on the uptake of 111In-anti-γH2AX-TAT or the control compound 111In-IgG-TAT. 
We observed increased uptake of 111In-anti-γH2AX-TAT, but not 111In-IgG-TAT in the whole 
pancreas in KPC mice bearing a tumour, compared to non-tumour-bearing animals (P<0.05; Fig. 
5C), consistent with a higher PanIN-3 burden in resected pancreata of PDAC patients. None of the 
other organs showed significant differences in uptake (P>0.05; Supplemental Fig. 5B), apart from 
some non-consistent variation in kidney and spleen values. 
  




Despite recent progress, there remains an urgent need for imaging methodologies for early 
detection of pancreatic ductal adenocarcinoma (27,28). Nearly a decade ago, Koorstra et al. 
described a hyperactivation of the DNA damage repair (DDR) machinery during PDAC 
development, with increasing expression of activated ATM (p(Ser1981)ATM), and its substrates 
pCHK2 and γH2AX in high-grade hyperplasias (PanIN-3 lesions) compared to normal tissue and 
low-grade PanINs, but less so in PDAC (18). This study was consistent with earlier data from 
Bartkova et al. who showed similar findings in a wide variety of other tumour types (15). Here, 
we confirmed that the KPC mouse model of PDAC replicates this biology, with a marked increase 
in γH2AX staining in PanIN-3 lesions. As in the human disease, DDR hyperactivation in KPC 
mice subsides in lesions reaching the PDAC stage. This offers the possibility to specifically 
visualise PanIN-3 precursor lesions, to complement currently employed imaging technologies, 
such as ultrasound, CT and MRI, that can only detect the later-stage, larger invasive PDAC lesions. 
We demonstrate here that γH2AX imaging using 111In-labelled, TAT-modified anti-
γH2AX IgG can be used to detect high-grade PanINs in vivo, due to the propensity of these lesions 
to express higher levels of the phosphorylated γH2AX protein. Earlier studies had already shown 
that the ubiquitously used PET imaging agent 18F-FDG does not allow clearly delineation of these 
precursor lesions (24). Although the differences in uptake of 111In-anti-γH2AX-TAT described in 
PanIN3 vs. other tissues are subtle there is a clear benefit shown in survival studies. Our results 
here in a pancreatic cancer model confirm our earlier findings obtained in Balb/neuT mice, a 
genetically engineered mouse model of HER2-driven breast cancer (20). Notably, as before, no 
toxicity was observed from targeting an antibody to a DDR protein (23). Modelling showed 
previously that 111In-anti-γH2AX-TAT caused no significant difference in DNA double strand 
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break (DSB) repair, or in clonogenic survival (29). On the other hand, we previously showed that, 
when increasing amount of 111In were attached to anti-γH2AX-TAT (up to 6 MB/μg), the Auger 
electron emissions from 111In could result in formation of additional DNA double strand break 
damage, and, consequently, more γH2AX foci, resulting in an autoamplificaiotn loop, and 
increased cell kill. A similar scenario may be proposed, where the DDR hyperactivation in pre-
tumorous lesions is targeted by this therapeutic version of anti-γH2AX-TAT. 
It is of note that we observed marked increases in total pancreatic uptake of 111In-anti-
γH2AX-TAT, where only a small portion of the pancreas is classed as diseased PanIN-3. In 
addition, we measured some signal in non-diseased pancreatic tissue in KPC mice, or in pancreas 
in naïve wild-type animals. This suggests that the uptake in the small PanIN-3 lesions is enough 
to enable macroscopic detection using the imaging agent. Importantly, it has been observed that, 
upon careful resection of whole pancreata, multiple advanced PanIN-3 lesions are the norm rather 
than the exception, and that PanINs are a disease that is able to spread through the entire ductal 
system (12,13), with densities of up to 0.16 lesions histologically detectable per cm2 (30). This 
may aid detection in the clinical setting. Here, they may be used in conjunction with CT and MRI-
based methods already in use for screening of high-risk patients, or aid as a guide for more invase 
sampling. In the former setting, the technology may also be used to further study the temporal 
relationship between PanIN3 burden and PDAC formation. In addition, detection of PanIN-3 
burden may act as a prompt or a therapy efficacy readout for PanIN-3 ablation therapies. 
Some of the limitations of our approach derive from the use of a whole antibody to target 
γH2AX. This makes it not only more difficult to produce than small molecule or peptide-based 
imaging vectors, but antibodies are generally slow to clear from blood circulation, and are taken 
up by the liver and spleen (7). This may limit the ability of any antibody-based imaging agent to 
by on January 10, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
19 
 
detect liver metastases. Nonetheless, the modified antibody we used here does afford an excellent 
selectivity and affinity (KD = 23 nM) for its target epitope. Meanwhile, no other imaging vectors 
have yet been identified that reliably detect γH2AX, or any other post-translational modifications 
of phosphorylated serines and threonines that make up the bulk of information passed on in the 
DDR signalling networks. 
Despite being well-characterised, γH2AX expression is mostly used in the context of DNA 
DSBs. However, γH2AX expression is not exclusively linked to DSBs, as it is also expressed 
around collapsed replication forks, and γH2AX expression can persist for hours or even days after 
any DSB have long since been repaired (21). Although it does raise a cautionary note for the 
interpretation of γH2AX imaging in general, this does not take away from its ability to act as a 
biomarker for pretumourous lesions, including PanIN-3s. It is also noteworthy that γH2AX 
expression is observed in the late stages of apoptosis, but we observed no correlation of apoptotic 
cells, as highlighted by activated caspase-3, with γH2AX staining or 111In-anti-γH2AX-TAT 
uptake, perhaps aided by the short-lived nature of late apoptotic cells, causing only little 
contribution to the macroscopic signal observed by autoradiography or SPECT imaging. In 
addition, we observed no γH2AX-positive micronuclei resulting from genomic instability that may 
confound the detection of DDR upregulation by non-invasive imaging (31). Finally, it has been 
described that multiple links exist between DNA damage signalling and inflammatory signalling, 
and that DDR signalling influences immune surveillance of tumour tissue (32). Moreover, 
pancreatic inflammation is a key risk factor for pancreatic cancer (33), and this inflammation can 
directly affect epithelial cells to generate reactive oxygen and nitrogen species that lead to DNA 
damage and result in genetic instability. However, we observed no γH2AX staining in lymphocyte 
infiltrates in KPC mouse pancreata, suggesting that ‒ at least in this setting ‒ imaging of PanIN-
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3s with 111In-anti-γH2AX-TAT may be independent of immune cell presence. In addition, we 
observed no increased uptake in mice with caerulein-induced acute pancreatitis. 
We have previously demonstrated that γH2AX imaging in PDAC can be used to detect 
DSB induction by cancer drugs or radiation (34). In clinical p ractice, this would enable early 
detection of treatment response, thereby allowing early switch to alternative therapies in non-
responding patients. We now demonstrate that γH2AX imaging may allow early detection of pre-
cancerous PanIN-3 precursor lesions. The data we present in this manuscript was obtained using a 
mouse model of PDAC only. Staining quantification we used here was distinct from the histo-
scores used by Koorstra et al. (18).  Although it mimics clinical tumorogenesis of PanINs to PDAC 
well, with similar γH2AX expression patterns, PET imaging with 89Zr-anti-γH2AX-TAT in PDAC 
patients, and correlation between ex vivo autoradiography and PanIN histopathology is the next 
necessary step to validate this technology for human use.  
In conclusion, we showed, for the first time, in a preclinical genetically engineered mouse model 
of PDAC, the possibility of imaging the hyperactivation of DNA damage repair signalling during 
pancreatic tumorigenesis, a direct result of genomic stress caused by oncogenic transformation. 
This novel tool may be used as a part of focussed surveillance in individuals at increased risk of 
developing PDAC. 
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KEY POINTS 
Question: Can DNA Damage hyperactivation in pre-invasive cancer precursor lesions act as as 
means of early detection of pancreatic cancer by molecular imaging? 
Pertinent Findings: In this study, we found that hyperactivation of DNA damage repair signalling 
in PanIN-3 lesions in a genetically engineered mouse model of spontaneous pancreatic ductal 
adenocarcinoma (PDAC) could be highlighted by molecular imaging, targeting γH2AX. This 
permitted to predict at an early stage which mice would develop PDAC. 
Implications for patient care: This method may allow early detection of cancer in high-risk patient 
groups.  
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Fig. 1 Representative examples of γH2AX staining in various types of tissue in KPC mouse 
pancreata. (brown: γH2AX, purple: nuclei). Arrowheads indicate PanIN-3 lesions (Lymph: area 
of focal lymphocyte infiltration). Scale bar indicates 100 μm. The bottom right panel indicates 
semi-quantification of the intensity of staining (n = 12). 
  







Fig. 2 Concurrently acquired 18F-FDG, 111In-anti-γH2AX-TAT (A, B) or 111In-IgG-TAT (C, D), 
and CT images of KPC mice. Representative examples of either younger (A, C) or older animals 
(B, D) are presented. Image are shown as coronal MIPs, superimposed on a three-dimensional 










Fig. 3 Ex vivo biodistribution data showing uptake of 111In in the pancreas of KPC mice versus 
age, after administration of either 111In-anti-γH2AX-TAT or 111In-anti-RIgG-TAT (5 MBq, 5 μg). 
Linear regression analysis showed no significant correlation of IgG control compound with age, 
but an increase of 111In-anti-γH2AX-TAT with age, corresponding to the increased hyperplastic 
high-grade PanIN load in these animals. 
  







Fig. 4 (A) H&E staining of a pancreas section from a 113-day old KPC mouse harvested 24 h post-
administration of 111In-anti-γH2AX-TAT, (B) identification of the various morpho-pathological 
features (Lymph. = Lymphocytes), (C) autoradiography image showing the distribution of 
radioactivity, and (D) immunofluorescence image showing γH2AX (green) and nuclei (blue). 
Additional sections are shown in Supplemental Fig. 6. (E) maginifacitons of histological areas in 
A-D. (F) Uptake of 111In-anti-γH2AX-TAT in various morpho-pathological features in KPC 
pancreata, measured by ex vivo autoradiography of pancreas sections. (G)  Uptake of 111In-IgG-
TAT in various morpho-pathological features in KPC pancreata, measured by ex vivo 
autoradiography of pancreas sections. 






Fig. 5 (A) Representative images of KPC mice aged between 66-77 days imaged by SPECT, 24 h 
after intravenous administration of 111In-anti-γH2AX-TAT. Age at the time of imaging, the length 
of survival before clinical symptom endpoints were reached, and the diagnosis at necropsy are 
indicated for each mouse. The pancreatic region is indicated by the white arrowhead and white 
dashed line in the first animal only. (Coronal MIPs are shown, an outline of a mouse is indicated 
for the first animal only). (B) Mice showing uptake of 111In-anti-γH2AX-TAT in the pancreas 
showed significantly shorter survival than those not showing pancreatic uptake (P = 0.0273). (C) 
111In-anti-γH2AX-TAT, but not 111In-IgG-TAT, is taken up more in pancreata of tumour-bearing 
KPC mice.  
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PET/SPECT/CT imaging was performed using a VECTor4 imaging system (MILabs) using a rat 
collimator with 1.8 mm pinholes. List-mode PET/SPECT data were acquired for 30 minutes and 
a CT image was then subsequently acquired (55 kV, 0.19 mA) on the same system. For the indium-
111 SPECT images, reconstructions were performed using a γ-ray energy window of 156–190 keV 
(background weight 2.5), 0.6 mm3 voxels, 128 subsets, and 2 iterations using the manufacturer’s 
POSEM reconstruction protocol.  For the fluorine-18 PET images, reconstructions were performed 
using energy windows of 460-562 keV (background weight 2.5), 0.8 mm3 voxels, 128 subsets, and 
5 iterations using the manufacturer’s POSEM reconstruction type. To allow accurate scaling and 
quantification, calibration factors (determined from phantoms) were applied to the data. PET and 
SPECT images were each registered to CT and then attenuation corrected. During each imaging 
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session, mice were kept under anaesthesia by inhalation of 2% isofluorane in air and maintained 
at 37°C. Images were processed and volume-of-interest analyses were performed using the PMod 
software package (version 3.807, PMOD Technologies). 
111In-anti-γH2AX-TAT and 18F-FDG imaging in ageing KPC mice 
At various ages (ranging from 70 to 224 days), KPC mice underwent dual-isotope (18F and 111In) 
PET/SPECT imaging at 1 h after administration of 18F-FDG, and at 24 h after injection of either 
111In-anti-γH2AX-TAT (n = 9) or 111In-anti-IgG-TAT (n = 8). After imaging, selected tissues and 
blood were harvested, and the percentage of the injected dose of radiolabelled compound per gram 
in each of them was determined. Pancreatic tissue was snap-frozen, cyrosectioned, and processed 
for autoradiography, γH2AX immunohistochemistry and haematoxylin and eosin (H&E) staining. 
 
 
111In-anti-γH2AX-TAT imaging and survival in KPC mice 
KPC mice (aged 66-77 days) without tumours were imaged by SPECT, 24 h after administration 
of 111In-anti-γH2AX-TAT (n = 10) or 111In-IgG-TAT (n = 8) as above. Survival of mice was 
followed for up to 64 days after SPECT imaging. Mice were euthanised when they showed the 
first clinical symptoms of disease. Diagnosis of PDAC was confirmed on necropsy. 
 
 
111In-anti-γH2AX-TAT imaging in tumour-bearing KPC mice 
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To evaluate the influence of an existing tumour on the uptake 111In-anti-γH2AX-TAT in KPC 
mice, animals were euthanised 24 h after intravenous administration of 111In-anti-γH2AX-TAT (n 
= 9) or 111In-IgG-TAT (n = 7). Selected organs and tissues were harvested and the percentage of 
the injected dose per gram of tissue was determined. Pancreata were measured with the tumour(s) 
if present. Tumour presence was confirmed on necropsy (10 mice with tumour and 6 mice without 
tumour were included in this study). 
 
 
111In-anti-γH2AX-TAT imaging in older wild type mice 
To determine the influence of age on the distribution of 111In-anti-γH2AX-TAT, three younger 
(aged 66-76 days) and three older (aged 500-506 days) mice were intravenously injected with 
111In-anti-γH2AX-TAT. 24 h later, selected organs and blood were harvested and the percentage 
of the injected dose per gram of tissue was determined. 
 
 
111In-anti-γH2AX-TAT imaging in mice with acute pancreatitits 
Caerulein, sulfated (MPBIO, UK) was dissolved in 0.9 % saline for an injectable dose of 50 ug/kg 
in 30 μL. C57BL/6 female mice, 10 weeks of age were injected (IP) with either caerulein or saline 
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over a period of 6 hours. At 7.5 hours post the initial caerulein or saline injection all mice were 
injected via the tail vein with 111In-DTPA-γH2Ax-TAT (4.5 MBq, 5ug). 
SPECT/CT images were acquired 24 h later, for approximately 30 min using a VECTor4CT 
scanner (MILabs, Utrecht, the Netherlands) as above. Immediately after imaging, mice were 
euthanised by cervical dislocation and selected organs, tissues and blood were removed. The 
samples were immediately rinsed with water, dried, and transferred into a pre-weighed counting 
tube. After weighing the filled counting tubes, the amount of radioactivity in each was measured 
using a HiDex gamma counter (Lablogic). Counts per minute were converted into radioactivity 
units (MBq) using calibration curves generated from known standards. These values were decay-
corrected to the time of injection, and the percentage of the injected dose per gram (%ID/g) of each 
sample was calculated. Pancreatic tissue was flash-frozen with dry ice and stored at -80°C until 
required for further processing. 
 
 
Ex vivo biodistribution experiments 
After imaging (unless long-term follow-up was necessary), mice were euthanised by cervical 
dislocation and selected organs, tissues and blood were removed. The samples were immediately 
rinsed with water, dried, and transferred into a pre-weighed counting tube. After weighing the 
filled counting tubes, the amount of radioactivity in each was measured using a 2480 WIZARD2 
(PerkinElmer) or HiDex gamma counter (Lablogic). Counts per minute were converted into 
radioactivity units (MBq) using calibration curves generated from known standards. These values 
were decay-corrected to the time of injection, and the percentage of the injected dose per gram 
(%ID/g) of each sample was calculated. Pancreatic tissue was flash-frozen with dry ice and stored 
at -80°C until required for further processing.  




Pancreases harvested from mice (n = 12) were flash frozen and 8 m sections were prepared using 
a cryostat. Sections were stored at -80C until use. Slides were allowed to reach room temperature 
for 10 minutes then washed briefly in phosphate-buffered saline (PBS) pH 7.4. The slides were 
fixed in 4% paraformaldehyde/PBS for 10 min, then washed three times in PBS for 5 min. Sections 
were permeabilized in 1% Triton X-100 for 10 min, washed, and non-specific binding was blocked 
by incubation of the slides in 2% BSA/PBS + 0.1% Triton X-100 for 1 h at 37°C. Slides were 
briefly allowed to dry and each section was isolated using a PAP pen.  To each appropriate section 
approximately 100 µL of primary anti-γH2AX monoclonal antibody (Merck, catalogue no. 05-
636, clone JBW301) diluted 1:250 in 2% BSA/PBS + 0.1% Triton X-100, or just 2% BSA/PBS + 
0.1% Triton X-100, was applied, and incubated for 1 h at 37°C. The slides were washed three 
times in PBS for 5 min and the secondary goat anti-mouse Alexa Fluor-488 antibody 
(ThermoFisher Scientific, catalogue no. A-11001) diluted 1:250 in 2% BSA/PBS was applied and 
incubated for 1 h at 37°C. The slides were then washed in PBS, excess fluid removed, mounted 
using Vectashield containing DAPI (Vector Laboratories, catalogue no. H-1200). Slides were 
stored at 4°C in the dark. Images were acquired using a Leica SP8 confocal fluorescent 
microscope. 
Autoradiography 
Sections of pancreas tissue were exposed to a storage phosphor screen (PerkinElmer) to generate 
autoradiographs. Quantification was performed in one section each from at least three animals (as 
indicated) by ImageJ, using regions-of-interest based on H&E-based morpho-pathological 
features. The average intensity per VOI was used as a metric, and converted to %ID/g using known 
standards. 
3,3’-Diaminobenzidine (DAB) and Haematoxylin Staining 
To prevent staining of endogenous peroxidases, pancreas sections were incubated with 1.5% H2O2 
for 15 minutes at room temperature and then rinsed with deionised water. Slides were briefly 
allowed to dry and each section was isolated using a PAP pen. Non-specific binding was blocked 
by incubation of the slides in 5% goat serum in PBS + 0.1% Tween-20 for 1 h at 37°C. To each 
section approximately 100 µL of primary anti-γH2AX monoclonal antibody (Merck, catalogue no. 
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05-636, clone JBW301) diluted 1:800 in 5% goat serum in PBS + 0.1% Tween-20, or just 5% goat 
serum in PBS + 0.1% Tween-20, was applied, and incubated for 1h at room temperature. The 
slides were washed three times in PBS for 5 min and the secondary goat anti-mouse antibody (BA-
9200, Vector Laboratories) diluted 1:250 in 5% goat serum in PBS + 0.1% Tween-20 was applied 
and incubated for 30 minutes at room temperature. The slides were then washed three times in 
PBS + 0.1% Tween-20 for 5 minutes. ABC-HRP (Vactastain Elite, ABC-HRP reagent, R.T.U. 
peroxidase, PK-7100) was then applied to each section and incubated for 30 minutes at room 
temperature. The slides were then washed three times in PBS + 0.1% Tween-20 for 5 minutes. 
DAB solution (Pierce, DAB substrate kit) was then applied to each section and incubated for 5 
minutes. The slides were then washed three times with deionised water for 5 min and then 
counterstained with haematoxylin for 2 minutes. Slides were washed in running tap water and then 
dehydrated with an increasing concentration gradient of ethanol. Slides were mounted using DPX 
mounting medium and then stored at 4°C in the dark. Images were acquired at a 20x magnification 
using an Aperio Slide Scanner (Leica Biosystems) and analysed using the Aperio ImageScope 
Viewer (Leica Biosystems). 
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Supplemental Fig. 1 
 
 
Supplemental Fig. 1 (A) Quantification of the extent of PanIN1, 2, and 3 involvement in KPC mice 
of varying ages shows a clear correlation of PanIN3 presentation with age (n = 12). (B) Consistent 
with higher γH2AX expression in PanIN3 lesions, uptake of 111In-γH2AX-TAT in pancreata of KPC 
mice correlates with the amount of PanIN3 lesions (n = 7). (C) Similarly, uptake of 111In-anti-
γH2AX-TAT, but not 111In-IgG-TAT, in KPC mouse pancreas decreases with an increasing amount 
of healthy pancreatic tissue (n = 7 and 5, respectively). (D) Corroborating these observations, 
there is a trend towards a correlation between the extent of PanIn3 lesions and 111In-γH2AX-TAT 
uptake in KPC mouse pancreas (n = 7 and 5, respectively). 
 
  




Supplemental Fig. 2 
 
 
Supplemental Fig. 2 Activated caspase-3 staining in KPC mouse pancreas sections reveals little 
to no caspase activation in two independent PanIN3 lesions. No correlation with tissue positive 
for γH2AX were observed. Scale bar indicates 50 μm. A negative control where the primary anti-
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Supplemental Fig. 3 
 
Supplemental Fig. 3: 111In-anti-γH2AX-TAT (A, B) or 111In-IgG-TAT (C, D) imaging in KPC mice. 
Representative examples of either younger (A, C) or older animals (B, D) are presented. Image 
are shown as coronal sections through the pancreas (indicated by the white arrowhead). 
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Supplemental Fig. 4 
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Supplemental Fig. 4 Biodistribution of 111In-anti-γH2AX-TAT (A), 111In-IgG-TAT (B), or 18F-FDG 
(C) in KPC animals of various ages. Results are expressed as the percentage of the injected dose 
per gram of tissue. (* significant correlation of %ID/g with age)  
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Supplemental Fig. 5 
 
 
Supplemental Fig. 5 (A) 111In-anti-γH2AX-TAT, but not 111In-IgG-TAT, is taken up more in 
pancreata of tumour-bearing KPC mice. The pressence of a tumour or lack thereof was confirmed 
on necropsy. (* P = 0.015) (B) The biodistribution of 111In-anti-γH2AX-TAT is not significantly 
different in older Balb/c wild type animals compared to younger mice. 





Supplemental Fig. 6 
 
Supplemental Fig. 6. As in Figure 4 A-C. Additional sections.  
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Supplemental Fig. 7 
 
 
Supplemental Fig. 7 (A) Representative SPECT/CT images of Balb/c mice, treated with caerulein 
or vehicle control, and imaged 24 h after administration of 111In-anti-γH2AX-TAT (5 MBq/μg) (B) 
Ex vivo biodistribution results follwing imaging in A. 
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Supplemental Fig. 8 
 
Supplemental Fig. 8 (A) KPC mice aged between 66-77 days were imaged by SPECT, 24 h after 
intravenous administration of 111In-anti-γH2AX-TAT. Age at the time of imaging, the length of 
survival before clinical symptom endpoints were reached, and the diagnosis at necropsy are 
indicated for each mouse (Coronal MIPs are shown, an outline of a mouse is indicated for the first 
animal only). (B) Similar as (a), but using 111In-IgG-TAT control compound. (C) The age at time 
of imaging was not significantly different between the different groups (ANOVA; P=0.99). (D) 
Survival after imaging was not significantly different in animals imaged with 111In-anti-γH2AX-
TAT or 111In-IgG-TAT (P=0.51) (E) Survival time after imaging did not correlate with the age at 
the time of the scan, in this set of animals. 
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